PARKINSON DISEASE (Disorder)Syn-GNCT07204652
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
An observational study of PARKINSON DISEASE (Disorder) and Parkinson, run by CND Life Sciences at 1 site in United States.
Trial summary
The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is: Can doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease?… Read more about this study
- Who is it for?
- Ages 40 to 99 years
- Conditions the study is for
- PARKINSON DISEASE (Disorder), Parkinson, Parkinson's Disease and Parkinsonism
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Sep 2025to Sep 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with clinically confirmed Parkinson's disease who are undergoing routine colonoscopies for standard medical care. Participants must be able to provide informed consent and understand that participation is voluntary and for research purposes.
Who may be able to join
- Adults 40 to 99 years of age
- Patients with a confirmed clinical diagnosis of Parkinson's disease by UKPDS Brain Bank Criteria
- Patients who have agreed to undergo a routine colonoscopy as part of their surveillance for colon cancer or exclusion of other gastrointestinal diseases
Who cannot join
- Use of anticoagulants (Plavix 75 mg or aspirin up to 325 mg alone is allowed)
- History of colon cancer
- Recent gastrointestinal illness or surgical procedures
- Pregnant or planning to become pregnant before the scheduled colonoscopy
- Significant cognitive impairment, as determined by study investigators
- Decisionally impaired adults who cannot express understanding that this study is voluntary and for research purposes
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Oregon Health & Science University
Portland, Oregon, 97239
Magda Armendariz Sullivan, 503-501-8478, armendam@ohsu.edu
Sarah Diamond, MD
About this study
Official title: Detection of Phosphorylated Alpha-synuclein Through Routine Colonoscopy to Diagnose Parkinson's Disease and Related Disorders
The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is:
Can doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease?
Currently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.
Read the detailed description
Brief Summary
What is this study about? This study is testing whether doctors can detect signs of Parkinson's disease by taking small tissue samples from the colon during a routine colonoscopy. Researchers want to see if they can find a specific protein called alpha-synuclein that builds up in people with Parkinson's disease.
Why is this study important? Currently, Parkinson's disease is diagnosed mainly by observing symptoms like tremors and movement problems. However, by the time these symptoms appear, the disease has already progressed significantly. Finding a way to detect the disease earlier could help doctors start treatment sooner and potentially slow down the disease.
Who can participate?
- Adults between 40-99 years old
- People who have already been diagnosed with Parkinson's disease
- People who are already scheduled to have a routine colonoscopy for colon cancer screening or other medical reasons
What happens during the study? Before the colonoscopy:
- Participants will complete questionnaires about their Parkinson's symptoms, sleep, and thinking abilities
- They will take a brief smell test
- They will collect a stool sample at home using a provided kit
During the colonoscopy:
- The colonoscopy procedure remains exactly the same as planned
- Doctors will take 4 additional small tissue samples (2 from each side of the colon)
- This adds only about 2 minutes to the procedure
After the colonoscopy:
- No additional visits are required
- The tissue samples will be tested for the alpha-synuclein protein
- Participants will not receive individual test results
What are the risks?
The main risks are the same as any routine colonoscopy, including:
- Discomfort during the procedure
- Very rare complications like bleeding or bowel perforation
- Small risk of infection
- Possible breach of medical privacy (researchers take steps to protect this)
What are the benefits?
- Participants help advance research that could lead to earlier detection of Parkinson's disease
- This could eventually help future patients get diagnosed and treated sooner
- There are no direct medical benefits to participants
How many people will be in this study? 20 people with Parkinson's disease will participate in this study at Oregon Health \& Science University (OHSU).
How long does participation take?
- One screening visit before the colonoscopy (about 1-2 hours)
- The colonoscopy procedure (same length as normally planned)
- Collecting a stool sample at home (one time)
This research is sponsored by CND Life Sciences and conducted at OHSU.
- Conditions
- PARKINSON DISEASE (Disorder), Parkinson, Parkinson's Disease and Parkinsonism, Parkinson Disease
- Being tested
- No Intervention: Observational Cohort
- Keywords
- Parkinson, Parkinson's Disease, Parkinson disease, Parkinson Disease (Disorder)
- Medical subject headings
- Parkinson Disease, Parkinsonian Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortDiagnostic test
No Intervention: Observational Cohort
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection of phosphorylated alpha-synuclein in colon tissue samples
Measured: At time of colonoscopy procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2025
- Study start3 Sep 2025
- Primary completionSep 2028 (estimated)
- Study completionSep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CND Life Sciences
- Sponsor type
- University, hospital or other
- Collaborators
- Oregon Health and Science University
- Responsible party
- Sponsor
- Investigators
- Delaram Safarpour, MD, MSCE, FAAN, Principal investigator, Oregon Health and Science University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07204652
- Sponsor's protocol ID
- OHSU IRB # 27731
- Acronym
- Syn-G
- Status last verified
- Feb 2026
- First submitted
- 24 Sep 2025
- Last updated
- 11 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Detection of Phosphorylated Alpha-synuclein Through Routine Colonoscopy to Diagnose Parkinson's Disease and Related Disorders
- ClinicalTrials.gov ID
- NCT07204652
- Acronym / sponsor ID
- Syn-G / OHSU IRB # 27731
- Conditions
- PARKINSON DISEASE (Disorder), Parkinson, Parkinson's Disease and Parkinsonism, Parkinson Disease
- Keywords
- Parkinson, Parkinson's Disease, Parkinson disease, Parkinson Disease (Disorder)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- CND Life SciencesUniversity, hospital or other
- Collaborators
- Oregon Health and Science University
- Study start
- 3 Sep 2025 (actual)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Sep 2029 (estimated)
- First posted
- 2 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is:
Can doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease?
Currently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.
Detailed description
Brief Summary
What is this study about? This study is testing whether doctors can detect signs of Parkinson's disease by taking small tissue samples from the colon during a routine colonoscopy. Researchers want to see if they can find a specific protein called alpha-synuclein that builds up in people with Parkinson's disease.
Why is this study important? Currently, Parkinson's disease is diagnosed mainly by observing symptoms like tremors and movement problems. However, by the time these symptoms appear, the disease has already progressed significantly. Finding a way to detect the disease earlier could help doctors start treatment sooner and potentially slow down the disease.
Who can participate?
- Adults between 40-99 years old
- People who have already been diagnosed with Parkinson's disease
- People who are already scheduled to have a routine colonoscopy for colon cancer screening or other medical reasons
What happens during the study? Before the colonoscopy:
- Participants will complete questionnaires about their Parkinson's symptoms, sleep, and thinking abilities
- They will take a brief smell test
- They will collect a stool sample at home using a provided kit
During the colonoscopy:
- The colonoscopy procedure remains exactly the same as planned
- Doctors will take 4 additional small tissue samples (2 from each side of the colon)
- This adds only about 2 minutes to the procedure
After the colonoscopy:
- No additional visits are required
- The tissue samples will be tested for the alpha-synuclein protein
- Participants will not receive individual test results
What are the risks?
The main risks are the same as any routine colonoscopy, including:
- Discomfort during the procedure
- Very rare complications like bleeding or bowel perforation
- Small risk of infection
- Possible breach of medical privacy (researchers take steps to protect this)
What are the benefits?
- Participants help advance research that could lead to earlier detection of Parkinson's disease
- This could eventually help future patients get diagnosed and treated sooner
- There are no direct medical benefits to participants
How many people will be in this study? 20 people with Parkinson's disease will participate in this study at Oregon Health \& Science University (OHSU).
How long does participation take?
- One screening visit before the colonoscopy (about 1-2 hours)
- The colonoscopy procedure (same length as normally planned)
- Collecting a stool sample at home (one time)
This research is sponsored by CND Life Sciences and conducted at OHSU.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 40 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with clinically confirmed Parkinson's disease who are undergoing routine colonoscopies for standard medical care. Participants must be able to provide informed consent and understand that participation is voluntary and for research purposes.
Key inclusion criteria (3 listed)
- Adults 40 to 99 years of age
- Patients with a confirmed clinical diagnosis of Parkinson's disease by UKPDS Brain Bank Criteria
- Patients who have agreed to undergo a routine colonoscopy as part of their surveillance for colon cancer or exclusion of other gastrointestinal diseases
Key exclusion criteria (6 listed)
- Use of anticoagulants (Plavix 75 mg or aspirin up to 325 mg alone is allowed)
- History of colon cancer
- Recent gastrointestinal illness or surgical procedures
- Pregnant or planning to become pregnant before the scheduled colonoscopy
- Significant cognitive impairment, as determined by study investigators
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortNo Intervention: Observational Cohort | Diagnostic test | – |
Primary outcome
Detection of phosphorylated alpha-synuclein in colon tissue samples
Time frame: At time of colonoscopy procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2026.
Related trials for PARKINSON DISEASE (Disorder)
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Delaram Safarpour, MD, MSCE, FAAN principal investigator
Oregon Health and Science University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of PARKINSON DISEASE (Disorder) and Parkinson, run by CND Life Sciences at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Magda Armendariz Sullivan (503-501-8478, armendam@ohsu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection of phosphorylated alpha-synuclein in colon tissue samples (time frame: At time of colonoscopy procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2026.